Shares of NRx Pharmaceuticals (NASDAQ:NRXP) jumped 11.8% as of the market close on Wednesday. The big gain came after the company announced positive safety findings from a late-stage study evaluating its drug Zyesami in combination with Gilead Sciences’ Veklury in treating hospitalized patients with acute respiratory failure due to COVID-19.
So what
NRx didn’t provide details from the late-stage study of Zyesami and Veklury. However, the company stated that the study’s Data Safety Monitoring Board has identified no new safety issues and is recommending moving forward with enrollment in the trial.
